Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597610 | 1.00 | ALDH1A1 (0.54) | ALDH1A1LGALS8KDM4ELMNAMAPT | |
| SCHEMBL18585777 | 1.00 | ALDH1A1 (0.54) | ALDH1A1LGALS8KDM4ELMNAMAPT | |
| Citric Acid SCHEMBL45492 | 0.76 | ALDH1A1 (0.94) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL27351141 | 0.75 | ALDH1A1 (0.65) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL27588804 | 0.74 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL27572383 | 0.74 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL3417196 | 0.74 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL934375 | 0.74 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL144692 | 0.74 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| Citric Acid SCHEMBL28604832 | 0.73 | ALDH1A1 (0.88) | ALDH1A1KDM4ELMNAMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113613510-B | Nutritional composition comprising 2 'fucosyllactose and 3' galactosyl lactose | N·V·努特里奇亚 | 2024-04-12 | — | — | CN | disclosed |
| US-20240050490-A1 | COMPOSITIONS AND METHODS | SERES THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4286014-A2 | NUTRITIONAL COMPOSITION COMPRISING 2'FUCOSYLLACTOSE AND 3'GALACTOSYLLACTOSE | N.V. Nutricia (NL) | 2023-12-06 | — | — | EP | disclosed |
| US-11730775-B2 | Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof | SERES THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3979827-B1 | NUTRITIONAL COMPOSITION COMPRISING 2'FUCOSYLLACTOSE AND 3'GALACTOSYLLACTOSE | NUTRICIA NV (NL) | 2023-08-02 | — | — | EP | disclosed |
| US-11666612-B2 | Network-based microbial compositions and methods | SERES THERAPEUTICS, INC (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4151097-A1 | NUTRITIONAL COMPOSITION COMPRISING 2'FUCOSYLLACTOSE AND DIETARY BUTYRATE | N.V. Nutricia (NL) | 2023-03-22 | — | — | EP | disclosed |
| US-20220249578-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF PATHOGENIC BACTERIAL GROWTH | SERES THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-11185562-B2 | Compositions and methods for inhibition of pathogenic bacterial growth | SERES THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3883393-A2 | NUTRITIONAL COMPOSITION COMPRISING 2'FUCOSYLLACTOSE AND DIETARY BUTYRATE | N.V. Nutricia (NL) | 2021-09-29 | — | — | EP | disclosed |
| US-9011834-B1 | Compositions and methods | Seres Health, Inc. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150093360-A1 | COMPOSITIONS AND METHODS | Seres Health, Inc. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140328803-A1 | Compositions and Methods | SERES THERAPEUTICS, INC. | 2014-11-06 | — | — | US | disclosed |
| WO-2014153194-A2 | METHODS FOR PATHOGEN DETECTION AND ENRICHMENT FROM MATERIALS AND COMPOSITIONS | Seres Health, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014145958-A2 | NETWORK-BASED MICROBIAL COMPOSITIONS AND METHODS | Seres Health, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014121301-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF PATHOGENIC BACTERIAL GROWTH | Seres Health, Inc. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014121302-A2 | COMPOSITIONS AND METHODS | Seres Health, Inc. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014121298-A2 | METHODS OF POPULATING A GASTROINTESTINAL TRACT | Seres Health, Inc. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2004002506-A1 | AGENT FOR CURING ANAPHLACTIC DISEASE AND HEALTH FOOD, AND MANUFACTURING PROCESS THEREOF | FUKUDA KOJI (JP) | 2004-01-08 | — | — | WO | disclosed |
| EP-0600992-B1 | USE OF GENTISIC ACID OR GENTISYL ALCOHOL FOR STABILISING RADIOLABELED PEPTIDES AND PROTEINS | MALLINCKRODT MEDICAL INC (US) | 2000-09-20 | — | — | EP | disclosed |